FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients
FDA chemistry reviewers in the Office of Generic Drugs provide an overview of common deficiences cited throughout the Chemistry, Manufacturing, and Controls section of ANDAs.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 45-51

Overages. One common deficiency is related to a proposed overage of the active. The firm should identify and justify any formulation overages that appear in the final product; and the overage should be further discussed with respect to the manufacturing process in 3.2.P.3. Note that, in general, the only acceptable justification for an overage in the final drug product formulation is if the ANDA sponsor demonstrates the same overage is also observed in the RLD. It is not acceptable to propose an overage to increase the shelf-life of the drug product. Generic sponsors should justify the proposed overage as compared to the RLD. Data that can be used to justify the overage may include comparative assay data on the test and reference products throughout shelf-life and comparative impurity/degradant levels demonstrating similar behavior. Other reported overages such as the use of excess coating solution in order to ensure uniform coating for product performance do require justification, and this information should be reported in the 3.2.P.1 and 3.2.P.3 sections, as applicable.

Comparison to RLD. Although questions with respect to comparability of the formulation to the RLD in certain dosage form are often addressed during filing of the ANDA, with the justification for the allowed exceptions per the Code of Federal Regulations (CFR) is often times lacking. 21 CFR 314.94 (9) (iii through v) includes a list of "exception excipients" or inactive ingredient differences permitted in a generic product when compared to the RLD (7). These regulations must be followed by the applicant in order to meet the requirements of classification as a generic product. In cases where the applicant is using an exception excipient the sponsor must demonstrate that the differences do not affect the safety or efficacy of the proposed drug product, as required by the CFR.

With respect to comparability of the active pharmaceutical ingredient (API) with the RLD product, this is outside the scope if this article, however, good references can be found in the "Orange Book" with respect to pharmaceutical equivalence. (8)

There are a few commonly cited questions with respect to Q1/ Q2 formulations and the use of "exception excipients". For example, the CFR allows substitution or addition of buffer, preservative or antioxidant in a parenteral dosage forms. However, the sponsor needs to be cognizant of the impact of this substitution or addition on the overall product performance.

The QbR FAQ includes additional recommendations for other allowed differences in solution formulations and bioequivalence impact (4). These include the amount of sorbitol or mannitol in an oral solution; the amount of penetration enhancer in a topical product; any Q1 or Q2 differences in an ophthalmic solution; and any Q1 or Q2 difference in inhalation and nasal spray products.

Finally, if there is any additional risk introduced by a proposed generic formulation, comments may be provided to the firm to justify that the use of the excipient will not introduce a higher risk product into the market. Examples may include the use of aspartame, castor oil, peanut oil, colorants (e.g., FD&C yellow #5), or benzyl alcohol, when they are not present in the new drug application (NDA) product.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here